Free, source-traceable HIV knowledge
Menu
AIDS Research CenterEvidence for public health. Knowledge for everyone.
Privacy: no trackingAccessibility StatementSubmit a Correction
AIDS Research CenterEvidence for public health. Knowledge for everyone.SearchLanguageHelp
AIDS Research CenterEvidence for public health. Knowledge for everyone.
English
LanguageEnglishDeutschFrançaisEspañol
Accessibility
Display preferencesStored only on this device.
SavedGet Help

Antiretroviral therapy

Treatment interruption risks

How treatment works, how regimens are selected, and what affects treatment success.

Publisher
The Bach Foundation
Audience
Public · Professional · Research
Last reviewed
18 August 2026
Status
Source-linked
Jurisdiction
Global context; local guidance may vary

Essential answer

Treatment interruption risks is part of the Center’s antiretroviral therapy record.

Antiretroviral therapy uses active medicines in combination to suppress HIV replication. Regimen selection depends on effectiveness, resistance, safety, interactions, preferences and reliable access.

Complete public explanation

How treatment works, how regimens are selected, and what affects treatment success.

Use the information with its source date, population and jurisdiction. A general explanation cannot determine an individual’s diagnosis, eligibility, regimen or legal obligations.

Key considerations

  • Durable suppression protects health and prevents sexual transmission.
  • Resistance can emerge when a regimen lacks sufficient activity.
  • Long-acting options change dosing burden but require planned follow-up and missed-dose management.
  • Interactions and side effects should be reviewed with a qualified professional.

Research and evidence questions

01How can regimens become longer acting, simpler and more forgiving?
02Which options remain effective with resistance or comorbidity?
03How can monitoring burden and cost be reduced safely?
04Which delivery models improve continuity during disruption?

Professional and academic evidence

Professional interpretation of treatment interruption risks adds study design, population, comparator, outcomes, statistical methods, limitations, conflicts, guideline adoption, geographic applicability, replication and integrity status.

Evidence record fields for Treatment interruption risks
FieldWhat the Center displays
Meaning and scopeDefinition, mechanism, intended use and what should not be inferred.
Population and jurisdictionAge, sex and gender, geography, HIV subtype, clinical context and issuing authority.
OutcomeClinical, virologic, diagnostic, public-health or implementation outcome and follow-up.
ProvenanceOriginal source, identifier, version, funding, conflicts, access date and review.
IntegrityProtocol changes, corrections, expressions of concern, retractions and later evidence.

Principal sources and evidence gateways

Links checked 18 August 2026
01
WHO updated recommendations on HIV clinical managementWorld Health Organization · Guideline · Access checked 18 Aug 2026
02
Clinical guidelines for HIV prevention and treatmentNIH Clinicalinfo · Guideline · Access checked 18 Aug 2026
03
Global HIV & AIDS statistics — 2025 reporting yearUNAIDS · Dataset · Access checked 18 Aug 2026
Additional permanent evidence gateways